06855 亞盛醫藥－Ｂ
按盘价 
42.760 0.000 (0.000%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -37.766% | -15.843% | -34.729% | -30.602% | -33.501% |
| 股东资金回报率 (%) | -156.455% | -249.796% | -394.665% | -107.451% | -75.184% |
| 资本运用回报率 (%) | -53.563% | -27.938% | -59.100% | -45.299% | -30.339% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 91.476% | 97.034% | 86.241% | 89.510% | 88.076% |
| 未计利息、税项、折旧及摊销前利润率 (%) | -205.172% | -28.062% | -350.068% | -372.380% | -2845.926% |
| 税前边际利润率 (%) | -215.294% | -40.305% | -420.238% | -423.045% | -2981.903% |
| 纯利率 (%) | -216.465% | -41.343% | -416.984% | -421.019% | -2803.382% |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 1.792 X | 1.264 X | 1.439 X | 1.857 X | 5.221 X |
| 速动比率 (X) | 1.774 X | 1.258 X | 1.422 X | 1.846 X | 5.210 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 66.338% | 89.527% | 97.175% | 85.561% | 58.003% |
| 总债项 / 总资产比率 (%) | 49.948% | 63.736% | 71.813% | 63.341% | 36.880% |
| 净债项 / 总资产比率 (%) | -12.372% | 15.558% | 28.066% | 10.617% | -22.433% |
| 总债项 / 股东资金比率 (%) | 149.473% | 631.542% | 2972.003% | 438.686% | 87.815% |
| 长期债项 / 股东资金比率 (%) | 57.173% | 336.660% | 1951.754% | 311.836% | 83.810% |
| 净债项 / 股东资金比率 (%) | -37.024% | 154.162% | 1161.531% | 73.530% | -53.415% |
| 净现金 / (债项) ($) | 4.90亿 | (4.07亿) | (7.02亿) | (3.00亿) | 6.60亿 |
| 每股净现金 / (债项) ($) | 1.314 | (1.292) | (2.418) | (1.133) | 2.509 |
| 总债项 / 资本运用比率 (%) | 85.325% | 114.974% | 114.645% | 91.977% | 42.044% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 131.324日 | 142.838日 | 153.054日 | 110.987日 | 431.025日 |
| 应收贸易帐周转率日数 (日) | 106.833日 | 42.624日 | 164.631日 | 94.268日 | 705.780日 |
| 应付贸易帐周转率日数 (日) | 63.164日 | 30.597日 | 138.121日 | 144.826日 | 616.106日 |
| 备注： | 实时报价更新时间为27/03/2026 07:52 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
